Company: OSRH
Filing Date: 2025-04-22
Form Type: 10-K
Source: 0001213900-25-034116
Chunk: 130

Company: OSR Holdings, Inc.
Filing Date: 2025-04-22
Form: 10-K
Item: Item 1
Chunk 130
---
 the potential commercial launch of the product or to meet potential
future demand. If our manufacturers are unable to produce sufficient quantities for clinical trials or for commercialization, our development
and commercialization efforts would be impaired, which would have an adverse effect on our business, financial condition, results of operations
and growth prospects.

67

Risks Related to the Company’s Intellectual Property

The following risk factors reference the risks and uncertainties
relating to the intellectual property of OSR, which, following the closing of the Business Combination, will be the intellectual property
of the Company. References in this section to “we,” “us,” and “our” refer to OSR prior to the closing
of the Business Combination and to the Company after closing.

If we are unable to obtain and maintain patent and other intellectual
property protection for our technology and product candidates or if the scope of the intellectual property protection obtained is not
sufficiently broad, we may not be able to compete effectively in our markets.

We rely upon a combination of patents, trademarks, trade secret protection
and confidentiality agreements with employees, consultants, collaborators, advisors and other third parties to protect the intellectual
property related to our product candidates. Our success depends in large part on our ability to obtain and maintain patent protection
in the United States and other countries with respect to our product candidates and any future product candidates. We also seek to
protect our proprietary position by in-licensing or acquiring intellectual property and filing patent applications in the United States
and abroad related to our development programs and product candidates. The patent prosecution process is expensive and time-consuming,
and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner.
Furthermore, there is always a risk that our licensed or owned issued patents and any pending and future patent applications may not protect
our product candidates, in whole or in part, and may not effectively prevent others from commercializing competitive product candidates,
or that an alteration to product candidates or processes may provide sufficient basis for a competitor to avoid infringing our patent
claims. The risks associated with patent rights generally apply to patent rights that we in-license now or in the future, as
well as patent rights that we may own now or in the future.

It is also possible that we will fail to identify patentable aspects
of our research and development output before it is too late to obtain patent protection. Although we enter into non-disclosure and
confidentiality